Design and Synthesis of Orexin 1 Receptor-Selective Agonists.
Keita IioKao HashimotoYasuyuki NagumoMao AmezawaTaisei HasegawaNaoshi YamamotoNoriki KutsumuraKatsuhiko TakeuchiYukiko IshikawaHikari YamamotoAkihisa TokudaTetsu SatoYasuo UchidaAsuka InoueRyuji TanimuraMasashi YanagisawaHiroshi NagaseTsuyoshi SaitohPublished in: Journal of medicinal chemistry (2023)
Orexins are a family of neuropeptides that regulate various physiological events, such as sleep/wakefulness as well as emotional and feeding behavior, and that act on two G-protein-coupled receptors, i.e., orexin 1 (OX 1 R) and orexin 2 receptors (OX 2 R). Since the discovery that dysfunction of the orexin/OX 2 R system causes the sleep disorder narcolepsy, several OX 2 R-selective and OX 1/2 R dual agonists have been disclosed. However, an OX 1 R-selective agonist has not yet been reported, despite the importance of the biological function of OX 1 R. Herein, we report the discovery of a potent OX 1 R-selective agonist, ( R , E )-3-(4-methoxy-3-( N -(8-(2-(3-methoxyphenyl)- N -methylacetamido)-5,6,7,8-tetrahydronaphthalen-2-yl)sulfamoyl)phenyl)- N -(pyridin-4-yl)acrylamide [( R )-YNT-3708; EC 50 = 7.48 nM for OX 1 R; OX 2 R/OX 1 R EC 50 ratio = 22.5]. The OX 1 R-selective agonist ( R )-YNT-3708 exhibited antinociceptive and reinforcing effects through the activation of OX 1 R in mice.